https://scholars.lib.ntu.edu.tw/handle/123456789/538752| Title: | Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era | Authors: | Kim D.-W. Banavali S.D. Bunworasate U. Goh Y.-T. Ganly P. Huang H. Irving I. Jootar S. Goh H.-G. Koh L.-P. Li W. Naoe T. Ng S.-C. Purushotaman V. Reksodiputro H. Shih L.-Y. JIH-LUH TANG Tojo A. Wang J. Wong R. |
Keywords: | Asia; Clinical practice; CML; Imatinib; Management; Survey; TKI | Issue Date: | 2010 | Journal Volume: | 34 | Journal Issue: | 11 | Start page/Pages: | 1459-1471 | Source: | Leukemia Research | Abstract: | Chronic myeloid leukemia (CML) management varies across Asia due to disparities in affluence and healthcare provision. We surveyed CML management practice at 33 hospitals in 14 countries/regions to identify treatment challenges and opportunities for harmonization.Patients were generally treated according to international guidelines; however, tyrosine kinase inhibitors (TKIs) and molecular monitoring are inaccessible to many patients not covered by national insurance or eligible for subsidized treatment. Late diagnosis and suboptimal monitoring, often due to cost and accessibility issues, are challenges. Priorities for Asia include: extending accessibility to TKIs; specialist laboratory monitoring; and enriching data to support regional CML management guidelines. ? 2010 Elsevier Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957018636&doi=10.1016%2fj.leukres.2010.03.033&partnerID=40&md5=e901982f16399bad2e8322bd129b5bc1 https://scholars.lib.ntu.edu.tw/handle/123456789/538752 |
ISSN: | 0145-2126 | DOI: | 10.1016/j.leukres.2010.03.033 | SDG/Keyword: | antineoplastic agent; bosutinib; busulfan; cyclopropanecarboxylic acid [4 [4 (4 methyl 1 piperazinyl) 6 (5 methyl 2h pyrazol 3 ylamino) 2 pyrimidinylthio]phenyl]amide; cytarabine; dasatinib; homoharringtonine; hydroxyurea; imatinib; interferon; iy 5511hcl; nilotinib; omectaxine; protein tyrosine kinase inhibitor; unclassified drug; protein kinase inhibitor; protein tyrosine kinase; adolescent; adult; aged; allogeneic hematopoietic stem cell transplantation; article; Asia; bone marrow biopsy; cancer epidemiology; child; chromosome analysis; chronic myeloid leukemia; controlled study; disease course; drug cost; drug efficacy; drug use; female; fluorescence in situ hybridization; health care access; health care disparity; health care distribution; health care practice; health insurance; health services research; health survey; histopathology; human; laboratory test; major clinical study; male; molecularly targeted therapy; mutational analysis; Pacific islands; polymerase chain reaction; priority journal; qualitative analysis; quantitative analysis; school child; sex ratio; treatment outcome; treatment response; unspecified side effect; antagonists and inhibitors; delayed diagnosis; drug delivery system; economics; information processing; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; patient care; Asia; Data Collection; Delayed Diagnosis; Drug Delivery Systems; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pacific Islands; Patient Care Management; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Asia; Data Collection; Delayed Diagnosis; Drug Delivery Systems; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pacific Islands; Patient Care Management; Protein Kinase Inhibitors; Protein-Tyrosine Kinases [SDGs]SDG3 |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.